Percheron Therapeutics, Invion explore novel cancer combination

Full story: https://grafa.com/en/news/australia/percheron-therapeutics-invion-explore-novel-cancer-combination

Percheron Therapeutics and Invion have agreed to evaluate a combination of their cancer therapies in preclinical studies.
Following the announcement, the Percheron Therapeutics share price was unchanged at $0.003.
Percheron stated that the study costs are expected to be modest and will not impact its cash runway.

Percheron Therapeutics (ASX:PER) has entered into a preclinical research collaboration with Invion (ASX:IVX) to evaluate its clinical-stage antibody HMBD-002 alongside Invion's photodynamic therapy Photosoft.

The agreement aims to build on a 2024 study at the Peter MacCallum Cancer Centre, which demonstrated superior tumour control when combining Invion's candidate with an immune checkpoint inhibitor compared to monotherapy alone.

Percheron Therapeutics stated that the costs of the study are expected to be modest and will not affect the company's cash runway.

Percheron Managing Director and CEO, Dr Michael Baker, commented, "Invion's Photosoft is designed to directly attack tumour tissue, while HMBD-002 modulates the immunosuppressive tumour microenvironment by blocking VISTA."

Both HMBD-002 and Invion's Photosoft candidate INV043 have already completed phase 1 clinical trials as individual monotherapies.

Following the announcement, the Percheron Therapeutics share price was unchanged at $0.003.

Percheron Therapeutics is an international biotechnology company focused on developing novel oncology therapies for solid tumours.

The company's primary lead candidate, HMBD-002, is designed to target VISTA to modulate immunosuppressive tumour microenvironments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":620287688257576,"tweetId":"620287688257576","gmtCreate":1792468120158,"gmtModify":1792468128257,"author":{"id":4169784042383112,"idStr":"4169784042383112","authorId":4169784042383112,"authorIdStr":"4169784042383112","name":"Grafa","avatar":"https://community-static.tradeup.com/news/ec1614006170d0aa3182195a94e8944d","vip":2,"userType":2,"introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":256,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/52e32e5a3b2f973a60d6968dbcabc08e","width":"1456","height":"816"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/52e32e5a3b2f973a60d6968dbcabc08e","width":"1456","height":"816"}],"title":"Percheron Therapeutics, Invion explore novel cancer combination","html":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/52e32e5a3b2f973a60d6968dbcabc08e\" tg-width=\"1456\" tg-height=\"816\"></p>\n<p>Full story: https://grafa.com/en/news/australia/percheron-therapeutics-invion-explore-novel-cancer-combination</p>\n<ul>\n <li>\n  <p>Percheron Therapeutics and Invion have agreed to evaluate a combination of their cancer therapies in preclinical studies.</p></li>\n <li>\n  <p>Following the announcement, the Percheron Therapeutics share price was unchanged at $0.003.</p></li>\n <li>\n  <p>Percheron stated that the study costs are expected to be modest and will not impact its cash runway.</p></li>\n</ul>\n<p style=\"text-align: start;\">Percheron Therapeutics (ASX:PER) has entered into a preclinical research collaboration with Invion (ASX:IVX) to evaluate its clinical-stage antibody HMBD-002 alongside Invion's photodynamic therapy Photosoft.</p>\n<p style=\"text-align: start;\">The agreement aims to build on a 2024 study at the Peter MacCallum Cancer Centre, which demonstrated superior tumour control when combining Invion's candidate with an immune checkpoint inhibitor compared to monotherapy alone.</p>\n<p style=\"text-align: start;\">Percheron Therapeutics stated that the costs of the study are expected to be modest and will not affect the company's cash runway.</p>\n<p style=\"text-align: start;\">Percheron Managing Director and CEO, Dr Michael Baker, commented, \"Invion's Photosoft is designed to directly attack tumour tissue, while HMBD-002 modulates the immunosuppressive tumour microenvironment by blocking VISTA.\"</p>\n<p style=\"text-align: start;\">Both HMBD-002 and Invion's Photosoft candidate INV043 have already completed phase 1 clinical trials as individual monotherapies.</p>\n<p style=\"text-align: start;\">Following the announcement, the Percheron Therapeutics share price was unchanged at $0.003.</p>\n<p style=\"text-align: start;\">Percheron Therapeutics is an international biotechnology company focused on developing novel oncology therapies for solid tumours.</p>\n<p style=\"text-align: start;\">The company's primary lead candidate, HMBD-002, is designed to target VISTA to modulate immunosuppressive tumour microenvironments.</p></body></html>","htmlText":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/52e32e5a3b2f973a60d6968dbcabc08e\" tg-width=\"1456\" tg-height=\"816\"></p>\n<p>Full story: https://grafa.com/en/news/australia/percheron-therapeutics-invion-explore-novel-cancer-combination</p>\n<ul>\n <li>\n  <p>Percheron Therapeutics and Invion have agreed to evaluate a combination of their cancer therapies in preclinical studies.</p></li>\n <li>\n  <p>Following the announcement, the Percheron Therapeutics share price was unchanged at $0.003.</p></li>\n <li>\n  <p>Percheron stated that the study costs are expected to be modest and will not impact its cash runway.</p></li>\n</ul>\n<p style=\"text-align: start;\">Percheron Therapeutics (ASX:PER) has entered into a preclinical research collaboration with Invion (ASX:IVX) to evaluate its clinical-stage antibody HMBD-002 alongside Invion's photodynamic therapy Photosoft.</p>\n<p style=\"text-align: start;\">The agreement aims to build on a 2024 study at the Peter MacCallum Cancer Centre, which demonstrated superior tumour control when combining Invion's candidate with an immune checkpoint inhibitor compared to monotherapy alone.</p>\n<p style=\"text-align: start;\">Percheron Therapeutics stated that the costs of the study are expected to be modest and will not affect the company's cash runway.</p>\n<p style=\"text-align: start;\">Percheron Managing Director and CEO, Dr Michael Baker, commented, \"Invion's Photosoft is designed to directly attack tumour tissue, while HMBD-002 modulates the immunosuppressive tumour microenvironment by blocking VISTA.\"</p>\n<p style=\"text-align: start;\">Both HMBD-002 and Invion's Photosoft candidate INV043 have already completed phase 1 clinical trials as individual monotherapies.</p>\n<p style=\"text-align: start;\">Following the announcement, the Percheron Therapeutics share price was unchanged at $0.003.</p>\n<p style=\"text-align: start;\">Percheron Therapeutics is an international biotechnology company focused on developing novel oncology therapies for solid tumours.</p>\n<p style=\"text-align: start;\">The company's primary lead candidate, HMBD-002, is designed to target VISTA to modulate immunosuppressive tumour microenvironments.</p></body></html>","text":"Full story: https://grafa.com/en/news/australia/percheron-therapeutics-invion-explore-novel-cancer-combination Percheron Therapeutics and Invion have agreed to evaluate a combination of their cancer therapies in preclinical studies. Following the announcement, the Percheron Therapeutics share price was unchanged at $0.003. Percheron stated that the study costs are expected to be modest and will not impact its cash runway. Percheron Therapeutics (ASX:PER) has entered into a preclinical research collaboration with Invion (ASX:IVX) to evaluate its clinical-stage antibody HMBD-002 alongside Invion's photodynamic therapy Photosoft. The agreement aims to build on a 2024 study at the Peter MacCallum Cancer Centre, which demonstrated superior tumour control when combining Invion's candidate with an immune checkpoint inhibitor compared to monotherapy alone. Percheron Therapeutics stated that the costs of the study are expected to be modest and will not affect the company's cash runway. Percheron Managing Director and CEO, Dr Michael Baker, commented, \"Invion's Photosoft is designed to directly attack tumour tissue, while HMBD-002 modulates the immunosuppressive tumour microenvironment by blocking VISTA.\" Both HMBD-002 and Invion's Photosoft candidate INV043 have already completed phase 1 clinical trials as individual monotherapies. Following the announcement, the Percheron Therapeutics share price was unchanged at $0.003. Percheron Therapeutics is an international biotechnology company focused on developing novel oncology therapies for solid tumours. The company's primary lead candidate, HMBD-002, is designed to target VISTA to modulate immunosuppressive tumour microenvironments.","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/620287688257576","repostId":0,"isVote":1,"tweetType":1,"viewCount":7,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1482,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/620287688257576"}